Searchable abstracts of presentations at key conferences in endocrinology

ea0056d5.2 | Pregnant women should be screened for thyroid hormones and antibodies | ECE2018

AGAINST: ‘Pregnant women should be screened for thyroid hormones and antibodies’

Velkeniers Brigitte , Unuane David

Screening is a process of identifying apparently healthy people at increased risk of a disease or condition. They can then be offered appropriate treatment to reduce the risk arising from the disease or condition.Thyroid autoimmunity (TAI), defined by the presence of antibodies against thyroperoxidase and thyroglobulin, have been associated with adverse pregnancy outcomes, infertility, and impaired child neurodevelopment. However, associations do not nec...

ea0064037 | The phenotypic diversity of the 22q11.2 deletion syndrome and hypoparathyrodism | BES2019

The phenotypic diversity of the 22q11.2 deletion syndrome and hypoparathyrodism

Sabrina Poradosu , Brigitte Velkeniers , Bert Bravenboer

The 22q11.2 deletion syndrome is a clinical syndrome caused by a hemizygous deletion in the chromosome 22q11.2. Clinical findings include cardiac defects, characteristic facial features, thymic hypoplasia, cleft palate, hypoparathyroidism, learning difficulties and psychiatric disorders. The importance of chromosome 22 relies on small number of genes located in the long (Q) arm participating in the development of the body plan, including the pharyngeal arches during the embryo...

ea0070aep792 | Reproductive and Developmental Endocrinology | ECE2020

Ovarian mucinous cystadenoma presenting with virilization

De Vis Maarten , Cosyns Stefan , Velkeniers Brigitte

Background: Ovarian mucinous cystadenomas are classically considered as ‘non-functional’ tumors. Cystadenomas are among the most common benign ovarian neoplasms. Compared with serous cystadenomas, mucinous cystadenomas occur less frequently, are more often unilateral and can attain an enormous size. Most of these tumors are asymptomatic and found incidentally on pelvic examination or with ultrasound. We present an unusual case of a mucinous cystadenoma presenting w...

ea0070aep1006 | Hot topics (including COVID-19) | ECE2020

Variable mineralocorticoid function in autoimmune Addison’s disease – a case report

De Rop Jonas , Unuane David , Velkeniers Brigitte

Autoimmune Addison’s disease (AAD) is widely believed to be associated with total loss of endogenous mineralocorticoid and glucocorticoid production and secretion, due to cell-mediated immune destruction. Therefore, patients with AAD are prescribed lifelong mineralocorticoid and glucocorticoid replacement therapy. We present a case of a 69 year old women known with polyglandular autoimmune disease type 2 (hypothyroidism, Addison’s disease and premature ovarian fail...

ea0073aep510 | Pituitary and Neuroendocrinology | ECE2021

Is this just vitiligo? Nelson is hiding

Vis Maarten De , Brigitte Velkeniers

A 64-year old man presented to our endocrinology clinic with progressive lumbar pain that had developed two months earlier. He had undergone bilateral adrenalectomy for Cushing disease and two years later transsphenoidal resection for Nelson tumor. On physical examination, the patient had remarkable hyperpigmentation due to ACTH hypersecretion periorbital, peri-auricular and in the lower-neck region. These findings were clearly evident in his case due to the extensive facial v...

ea0022s13.3 | The TSH reference range | ECE2010

A critical synopsis of meta-analysis in the field of subclinical thyroid disease

Velkeniers Brigitte , Van Meerhaeghe Alain , Unuane David , Haentjens Patrick

Background: Currently, physicians remain uncertain whether to screen and/or treat subclinical thyroid disease. Many observational studies, including cross-sectional, case–control, and prospective cohort studies, have reported on the association between subclinical thyroid disease and an ‘outcome of interest’. All cause mortality, coronary heart disease, fracture risk, and pregnancy outcome may drive the decision to screen or treat subclinical thyroid disease.</p...

ea0057011 | Radioiodine treatment for euthyroid goiter: The evolution of thyroid volume, tests and occurrence of autoimmunity | BES2018

Radioiodine treatment for euthyroid goiter: The evolution of thyroid volume, tests and occurrence of autoimmunity

Elke Decommer , Hendrik Everaert , Steven Raeymaeckers , Brigitte Velkeniers

Background: In Belgium, a land with borderline iodine intake, the prevalence of goiter is 6 to 40%. This raises the question of an economically affordable treatment with few side effects. In euthyroid goiters, the effect of radioiodine on volume reduction is debated. Most data were described last century and do not take into account recent thyroid hormone measurements, newer ultrasonography techniques and changes in iodine supplementation. Doses administered in the past and el...

ea0056p701 | Clinical case reports - Pituitary/Adrenal | ECE2018

A case of hypothalamic-pituitary disease: who’s the deceiving suspect?

Van Meerhaeghe Tess , De Schepper Jean , Velkeniers Brigitte

Introduction: Diagnosis and treatment of neurosarcoidosis (NS) can be challenging. We describe an unsual presentation of an isolated NS in a 21 year old adult, initially presenting with central diabetes insipidus (DI) associated with a stalk thickening at the age of 14.Case description: A 21 year old patient was first seen at the department of endocrinology after a 9 years follow-up for panhypopituitarism. He presented at the age of 14 years at the pedia...

ea0064009 | Risk of Malignancy of the Thyroid Nodule Evaluated by Scintigraphy | BES2019

Risk of Malignancy of the Thyroid Nodule Evaluated by Scintigraphy

Elias De Meyst , Bert Bravenboer , Marleen Keyaerts , Steven Raeymaeckers , Brigitte Velkeniers , Corina Andreescu

Background: Thyroid nodules are a common finding in clinical practice. Among classic risk factors for thyroid cancer, thyroid scintigraphy has traditionally been attributed prognostic value, with cold nodules implying greater risk. However, research supporting this assumption is of considerable age and possibly influenced by selection bias. In this study, we aimed to calculate the risk of malignancy in cold and hot nodules.Material and Methods: All thyro...

ea0064017 | Value of [11C]-methionine PET/CT in preoperative localization of adenomas in primary hyperparathyroidism | BES2019

Value of [11C]-methionine PET/CT in preoperative localization of adenomas in primary hyperparathyroidism

Julie Saerens , Brigitte Velkeniers , Marian Vanhoeij , Marleen Keyaerts , Steven Raeymaeckers , Bert Bravenboer

Introduction: The first-line imaging modalities to locate adenomas preoperatively in primary hyperparathyroidism (PHPT) are ultrasonography (US) and subtraction scintigraphy (SuSc). When these contradict each other or are inconclusive an [11C]-methionine PET/CT (MET-PET/CT) or a 4-dimensional computed tomography (4D-CT) can be performed.Objectives: The aim of this retrospective study was to evaluate the value of MET-PET/CT in the preoperative localizatio...